In 2022, three antiviral drugs-molnupiravir, remdesivir and nirmatrelvir/ritonavir-were introduced for treatment of mild-to-moderate COVID-19 in high-risk patients. The aim of this study is the evaluation of their effectiveness and tolerability in a real-life setting. A single-center observational study was set up, with the involvement of 1118 patients, with complete follow-up data, treated between the 5th of January and the 3rd of October 2022 at Santa Maria Goretti's hospital in Latina, Central Italy. A univariable and a multivariable analysis were performed on clinical and demographic data and composite outcome, the persistence of symptoms at 30 days and time to negativization, respectively. The three antivirals showed a similar effectiveness in containing the progression of the infection to severe COVID-19 and a good tolerability in the absence of serious adverse effects. Persistence of symptoms after 30 days was more common in females than males and less common in patients treated with molnupiravir and nirmatrelvir/r. The availability of different antiviral molecules is a strong tool and, if correctly prescribed, they can have a significant role in changing the natural history of infection for frail persons, in which vaccination could be not sufficient for the prevention of severe COVID-19.

Effectiveness, tolerability and prescribing choice of antiviral molecules molnupiravir, remdesivir and nirmatrelvir/r. A real-world comparison in the first ten months of use / Del Borgo, Cosmo; Garattini, Silvia; Bortignon, Carolina; Carraro, Anna; Di Trento, Daniela; Gasperin, Andrea; Grimaldi, Alessandra; De Maria, Sara Giovanna; Corazza, Sara; Tieghi, Tiziana; Belvisi, Valeria; Kertusha, Blerta; De Masi, Margherita; D’Onofrio, Ombretta; Bagaglini, Gabriele; Bonanni, Gabriella; Zuccalà, Paola; Fabietti, Paolo; Tortellini, Eeva; Guardiani, Mariasilvia; Spagnoli, Alessandra; Marocco, Raffaella; Alunni Fegatelli, Danilo; Lichtner, Miriam. - In: VIRUSES. - ISSN 1999-4915. - 15:4(2023), pp. 1-15. [10.3390/v15041025]

Effectiveness, tolerability and prescribing choice of antiviral molecules molnupiravir, remdesivir and nirmatrelvir/r. A real-world comparison in the first ten months of use

Garattini, Silvia;Carraro, Anna;Di Trento, Daniela;Gasperin, Andrea;De Maria, Sara Giovanna;Corazza, Sara;Tieghi, Tiziana;Belvisi, Valeria;Kertusha, Blerta;De Masi, Margherita;Bagaglini, Gabriele;Fabietti, Paolo;Tortellini, Eeva;Guardiani, Mariasilvia;Spagnoli, Alessandra;Marocco, Raffaella;Alunni Fegatelli, Danilo;Lichtner, Miriam
2023

Abstract

In 2022, three antiviral drugs-molnupiravir, remdesivir and nirmatrelvir/ritonavir-were introduced for treatment of mild-to-moderate COVID-19 in high-risk patients. The aim of this study is the evaluation of their effectiveness and tolerability in a real-life setting. A single-center observational study was set up, with the involvement of 1118 patients, with complete follow-up data, treated between the 5th of January and the 3rd of October 2022 at Santa Maria Goretti's hospital in Latina, Central Italy. A univariable and a multivariable analysis were performed on clinical and demographic data and composite outcome, the persistence of symptoms at 30 days and time to negativization, respectively. The three antivirals showed a similar effectiveness in containing the progression of the infection to severe COVID-19 and a good tolerability in the absence of serious adverse effects. Persistence of symptoms after 30 days was more common in females than males and less common in patients treated with molnupiravir and nirmatrelvir/r. The availability of different antiviral molecules is a strong tool and, if correctly prescribed, they can have a significant role in changing the natural history of infection for frail persons, in which vaccination could be not sufficient for the prevention of severe COVID-19.
2023
covid-19; sars-cov2; antivirals; early therapy; molnupiravir; nirmaltrelvir/ritonavir; remdesivir
01 Pubblicazione su rivista::01a Articolo in rivista
Effectiveness, tolerability and prescribing choice of antiviral molecules molnupiravir, remdesivir and nirmatrelvir/r. A real-world comparison in the first ten months of use / Del Borgo, Cosmo; Garattini, Silvia; Bortignon, Carolina; Carraro, Anna; Di Trento, Daniela; Gasperin, Andrea; Grimaldi, Alessandra; De Maria, Sara Giovanna; Corazza, Sara; Tieghi, Tiziana; Belvisi, Valeria; Kertusha, Blerta; De Masi, Margherita; D’Onofrio, Ombretta; Bagaglini, Gabriele; Bonanni, Gabriella; Zuccalà, Paola; Fabietti, Paolo; Tortellini, Eeva; Guardiani, Mariasilvia; Spagnoli, Alessandra; Marocco, Raffaella; Alunni Fegatelli, Danilo; Lichtner, Miriam. - In: VIRUSES. - ISSN 1999-4915. - 15:4(2023), pp. 1-15. [10.3390/v15041025]
File allegati a questo prodotto
File Dimensione Formato  
Del Borgo_Effectiveness_2023.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 275.8 kB
Formato Adobe PDF
275.8 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1700494
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 6
social impact